Drug intelligence / Profile preview

Streptamer-selected multi-antigen specific T cells

Development stage: Unknown
Lead developer: University Hospital Würzburg
Modality: Cell Therapies
Administration: Intravenous

Overview

Streptamer-selected multi-antigen specific T cells is an investigational adoptive cell therapy being developed by University Hospital Wuerzburg. The product consists of donor-derived CD8+ T cells selected using MHC-I Streptamer technology—reversible HLA/peptide multimers that allow for the isolation of antigen-specific T cells while maintaining their functional state by avoiding prolonged T-cell receptor (TCR) signaling. This multi-antigen-specific product targets a broad range of biological markers, including viral antigens from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus, as well as tumor-associated antigens (TAA) and minor histocompatibility antigens (MiHA). It is currently being evaluated in a Phase 1 clinical trial for adults with acute myeloid leukemia (AML) in first complete remission following T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT), with the aim of preventing viral infections and disease relapse while minimizing the risk of graft-versus-host disease (GvHD).

Other names: Streptamer-selected multi-antigen specific T cells after T cell depleted allo-SCTdonor-derived Streptamer-selected multi-antigen specific T cells

Targets

pMHC-I (Peptide–MHC class I complex)Adenovirus peptide-MHC class I complexes

Beyond the preview

Go deeper on Streptamer-selected multi-antigen specific T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptamer-selected multi-antigen specific T cells.

Explore the full profile